Enzymatica Publ (Sweden) Insiders
ENZY Stock | SEK 1.67 0.07 4.02% |
Enzymatica Publ employs about 23 people. The company is managed by 14 executives with a total tenure of roughly 110 years, averaging almost 7.0 years of service per executive, having 1.64 employees per reported executive. Breaking down Enzymatica Publ's management performance can provide insight into the firm performance.
Fredrik Lindberg CEO Chief Executive Officer |
Bengt Baron Chairman Independent Chairman of the Board |
Enzymatica |
Enzymatica Publ Management Team Effectiveness
The company has return on total asset (ROA) of (0.1909) % which means that it has lost $0.1909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4032) %, meaning that it generated substantial loss on money invested by shareholders. Enzymatica Publ's management efficiency ratios could be used to measure how well Enzymatica Publ manages its routine affairs as well as how well it operates its assets and liabilities.Enzymatica Publ Workforce Comparison
Enzymatica publ AB is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 207. Enzymatica Publ retains roughly 23.0 in number of employees claiming about 11% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.12. Enzymatica publ AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Enzymatica publ AB Price Series Summation is a cross summation of Enzymatica Publ price series and its benchmark/peer.
Enzymatica Publ Notable Stakeholders
An Enzymatica Publ stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enzymatica Publ often face trade-offs trying to please all of them. Enzymatica Publ's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enzymatica Publ's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Fredrik Lindberg | Chief Executive Officer | Profile | |
Bengt Baron | Independent Chairman of the Board | Profile | |
Mats Clarsund | Executive Vice President for Research and Development | Profile | |
Ulf Blom | Executive Vice President Marketing and Operations | Profile | |
Anna Isaksson | Vice President Quality and Regulatory Management | Profile | |
Jorgen Rexo | Executive Vice President Legal, Director | Profile | |
Johan Lindvall | Chief Operating Officer, Executive Vice President | Profile | |
Therese Filmersson | Chief Financial Officer | Profile | |
Louise Nicolin | Director | Profile | |
Marianne Alexandersson | Independent Director | Profile | |
Gudmundur Palmason | Director | Profile | |
Mats Andersson | Director | Profile | |
Stefan Olsson | Communication Mang | Profile | |
Claus Egstrand | Chief Commercial Officer | Profile |
About Enzymatica Publ Management Performance
The success or failure of an entity such as Enzymatica publ AB often depends on how effective the management is. Enzymatica Publ management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enzymatica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enzymatica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 24 people.
Please note, the imprecision that can be found in Enzymatica Publ's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enzymatica publ AB. Check Enzymatica Publ's Beneish M Score to see the likelihood of Enzymatica Publ's management manipulating its earnings.
Enzymatica Publ Workforce Analysis
Traditionally, organizations such as Enzymatica Publ use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enzymatica Publ within its industry.Enzymatica Publ Manpower Efficiency
Return on Enzymatica Publ Manpower
Revenue Per Employee | 2.5M | |
Revenue Per Executive | 4.1M | |
Net Loss Per Employee | 2M | |
Net Loss Per Executive | 3.2M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 4.6M |
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.